References

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

10.1038/nrmicro2236 · 2009 · External reference

Introduction to network meta-analysis: understanding what it is, how it is done, and how it can be used for decision-making

10.1093/aje/kwae260 · 2025 · External reference

Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis-United State

10.15585/mmwr.mm7108a1 · 2022 · External reference

Risk-stratified treatment for drug-susceptible pulmonary tuberculosis

10.1038/s41467-024-53273-7 · 2024 · External reference

Conceptual and technical challenges in network meta-analysis

10.7326/0003-4819-159-2-201307160-00008 · 2013 · External reference

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells

10.1038/nrmicro3200 · 2014 · External reference

Anti-tuberculosis treatment strategies and drug development: challenges and priorities

10.1038/s41579-022-00731-y · 2022 · External reference

Meta-analysis in clinical trials

10.1016/0197-2456(86)90046-2 · 1986 · External reference

Checking consistency in mixed treatment comparison meta-analysis

10.1002/sim.3767 · 2010 · External reference

Four-month rifapentine regimens with or without moxifloxacin for tuberculosis

10.1056/nejmoa2033400 · 2021 · External reference

Network meta-analysis: a powerful tool for clinicians, decision-makers, and methodologists

10.1016/j.jclinepi.2024.111537 · 2024 · External reference

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

10.1056/nejmoa1407426 · 2014 · External reference

Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis

10.1002/14651858.cd012918.pub2 · 2019 · External reference

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

10.1002/jrsm.1044 · 2012 · External reference

Quantifying heterogeneity in a meta-analysis

10.1002/sim.1186 · 2002 · External reference

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

10.1038/s41591-018-0224-2 · 2018 · External reference

The Hartung-Knapp-Sidik-Jonkman method for random-effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method

10.1186/1471-2288-14-25 · 2014 · External reference

Randomized clinical trial of thrice-weekly 4-month moxifloxacin- or gatifloxacin-containing regimens in the treatment of new sputum-positive pulmonary tuberculosis

10.1371/journal.pone.0067030 · 2013 · External reference

Four-month high-dose rifampicin regimens for pulmonary tuberculosis

10.1056/evidoa2300054 · 2023 · External reference

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

10.1056/nejmoa1314210 · 2014 · External reference

Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis

10.1371/journal.pmed.1000146 · 2009 · External reference

A four-month gatifloxacin-containing regimen for treating tuberculosis

10.1056/nejmoa1315817 · 2014 · External reference

The chemotherapy of tuberculosis: past, present and future

10.5588/ijtld.12.0083 · 2012 · External reference

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis

10.1093/cid/ciw376 · 2016 · External reference

CINeMA: an approach for assessing confidence in the results of a network meta-analysis

10.1371/journal.pmed.1003082 · 2020 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1136/bmj.n71 · 2021 · External reference

Serum drug concentrations predictive of pulmonary tuberculosis outcomes

10.1093/infdis/jit352 · 2013 · External reference

Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial

10.1016/s1473-3099(25)00151-3 · 2025 · External reference

Treatment strategy for rifampin-susceptible tuberculosis

10.1056/nejmoa2212537 · 2023 · External reference

The association between sterilizing activity and drug distribution into tuberculosis lesions

10.1038/nm.3937 · 2015 · External reference

Ranking treatments in frequentist network meta-analysis works without resampling methods

10.1186/s12874-015-0060-8 · 2015 · External reference

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

10.1002/jrsm.1037 · 2012 · External reference

Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS/CDC/ERS/IDSA clinical practice guideline

10.1164/rccm.202410-2096st · 2025 · External reference

Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials

10.1002/cpt.634 · 2017 · External reference

Tuberculosis treatment-shortening

10.1016/j.drudis.2024.103955 · 2024 · External reference

RoB 2: a revised tool for assessing risk of bias in randomised trials

10.1136/bmj.l4898 · 2019 · External reference

Risk factors for pulmonary tuberculosis recurrence, relapse, and reinfection: a systematic review and meta-analysis

10.1136/bmjresp-2023-002281 · 2024 · External reference

Recurrent tuberculosis: a systematic review and meta-analysis of incidence rates and the proportions of relapses and reinfections

10.1136/thoraxjnl-2020-215449 · 2021 · External reference

Four-month moxifloxacin-containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India: a randomized clinical trial

10.1111/tmi.13371 · 2020 · External reference

Predicting the outcome of therapy for pulmonary tuberculosis

10.1164/ajrccm.161.4.9903087 · 2000 · External reference

Unresolved reference

External reference